The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,900.00
Bid: 4,899.00
Ask: 4,902.00
Change: 37.00 (0.76%)
Spread: 3.00 (0.061%)
Open: 4,846.00
High: 4,917.00
Low: 4,836.00
Prev. Close: 4,863.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

9 Jun 2023 07:00

RNS Number : 2354C
Croda International PLC
09 June 2023
 

9 June 2023

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 (as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018).

 

Croda International Plc

 

Trading update

 

Croda International Plc ('Croda' or 'the Group') today provides an update on trading for the period ending 31 May 2023.

 

In Consumer Care, whilst sales volumes are up compared to the final quarter of 2022, they remain down double-digit percentage compared with the same period last year as a result of customer destocking continuing through the second quarter. Price increases implemented in 2022 and favourable foreign exchange rates so far in 2023 have helped to offset this impact, with revenues broadly flat versus the first five months of 2022. However, principally due to the lower sales volumes, operating profit margin has remained at a similar level to the second half of 2022.

 

In Life Sciences, Crop Protection started the year well, but the business is now experiencing rapid customer destocking, which was a factor originally expected to materialise more gradually later in the year. Life Sciences' operating profit margin is being negatively impacted by adverse mix in the year to date including lower sales for Covid-19 applications in the Pharma business. Shipments of lipid systems to our principal Covid vaccine customers are expected to occur as planned in the second half of 2023.

 

As a result of these factors, the Group generated £143m profit before tax in the first five months of the year, supported by minimal net finance costs. With customer destocking in consumer and industrial end-markets now expected to continue into the second half year and momentum moderating in Crop Protection, full year 2023 Group profit before tax is now expected to be between £370m and £400m.

 

Croda will report half year results for the six months to 30 June on 25 July 2023. 

 

The person responsible for making this announcement is Louisa Burdett, Chief Financial Officer.

Further information:

 

There will be a conference call for covering analysts at 0800 BST this morning with dial-in details below. Participants are encouraged to dial in early as they will need to register with the moderator.

· Operator Assisted Dial-In:

· United Kingdom (Local): +44 20 3936 2999

· United Kingdom (Toll-Free): +44 800 358 1035

· Global Dial-In Numbers

· Access Code: 360297

 

For enquiries contact:

 

Investors:

David Bishop, Croda

+44 7823 874428

Press:

Charlie Armitstead, Teneo

+44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSISLUEDSEFM
Date   Source Headline
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:00 amRNSDirector/PDMR Shareholding
6th Mar 20199:58 amRNSDirector/PDMR Shareholding
6th Mar 20199:57 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSResults for the year ended 31 December 2018
12th Feb 20194:47 pmRNSDirector/PDMR Shareholding
11th Jan 20194:21 pmRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSAcquisition completion
17th Dec 20187:00 amRNSAcquisition of global vaccine adjuvant specialist
12th Dec 20181:14 pmRNSDirector/PDMR Shareholding
22nd Nov 20181:54 pmRNSDirector Declaration
22nd Nov 20188:07 amRNSDirector/PDMR Shareholding
14th Nov 20182:48 pmRNSDirector/PDMR Shareholding
14th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSTrading Update for the Third Quarter 2018
26th Oct 20187:00 amRNSAcquisition update
12th Oct 20181:42 pmRNSDirector/PDMR Shareholding
4th Oct 20183:03 pmRNSDirector/PDMR Shareholding
4th Oct 20183:01 pmRNSDirector/PDMR Shareholding
28th Sep 20183:35 pmRNSDirector/PDMR Shareholding
11th Sep 20184:50 pmRNSDirector/PDMR Shareholding
6th Sep 20184:07 pmRNSDirector/PDMR Shareholding
5th Sep 20187:00 amRNSAppointment of Broker
22nd Aug 201811:06 amRNSDirector Declaration
13th Aug 20184:37 pmRNSDirector/PDMR Shareholding
7th Aug 20189:11 amRNSDirector/PDMR Shareholding
31st Jul 20184:16 pmRNSDirector/PDMR Shareholding
25th Jul 20184:19 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20182:27 pmRNSDirector/PDMR Shareholding
21st Jun 20187:00 amRNSDirector/PDMR Shareholding
12th Jun 20184:04 pmRNSDirector/PDMR Shareholding
11th Jun 20182:02 pmRNSDirector/PDMR Shareholding
31st May 20183:41 pmRNSDirector/PDMR Shareholding
25th May 20182:09 pmRNSDirector/PDMR Shareholding
11th May 20184:31 pmRNSDirector/PDMR Shareholding
26th Apr 20183:57 pmRNSDirector/PDMR Shareholding
26th Apr 20189:16 amRNSResult of AGM
25th Apr 20187:00 amRNSTrading Update for the First Quarter 2018
20th Apr 201811:14 amRNSDirectorate Change
20th Apr 20187:00 amRNSDirectorate Change
19th Apr 20189:47 amRNSDirector/PDMR Shareholding
19th Apr 20189:44 amRNSDirector/PDMR Shareholding
11th Apr 20181:09 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSCapital Markets Event
3rd Apr 20182:19 pmRNSDirector/PDMR Shareholding
28th Mar 20182:39 pmRNSDirector/PDMR Shareholding
28th Mar 20182:38 pmRNSDirector/PDMR Shareholding
28th Mar 201812:19 pmRNSScheme of Arrangement becomes Effective

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.